Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
5 clinical trials · Condition
◉ Watch Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT02567422) | National Cancer Institute (NCI) | 2017-04-17 |
| Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma (NCT02775812) | National Cancer Institute (NCI) | 2016-11-28 |
| Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (NCT02381535) | National Cancer Institute (NCI) | 2015-10-22 |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (NCT01810913) | National Cancer Institute (NCI) | 2013-03-22 |
Track Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 automatically
Every clearance here is in the API, with alerts when new ones post.